albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (clinicaltrials.gov) - P2/3 | N=560 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Ruijin Hospital | N=20 ➔ 60 | Not yet recruiting ➔ Recruiting

Enrollment change • Enrollment open • Oncology • Pancreatic Cancer • Solid Tumor

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy (clinicaltrials.gov) - P3 | N=430 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Shandong Public Health Clinical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma. (PubMed, Front Pharmacol) - "Dosing regimen: nimotuzumab (400 mg, Q3W) plus chemotherapy (nab-paclitaxel: 240 mg/m2, paclitaxel liposome: 135-175 mg/m2, platinum: 200-400 mg/m2, Q3W) and immunotherapy (PD-1/PD-L1: 200-240 mg, Q3W). 14 (25.5%) patients developed Grade 3-5 adverse events (AEs) not related to nimotuzumab, no serious AEs or deaths occurred. Our treatment combination for advanced ESCC showed a favorable survival profile, and safety was tolerable."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Evolving survival patterns in pancreatic adenocarcinoma: a 23-year retrospective observational analysis. (PubMed, J Gastrointest Oncol) - "Since 2011, FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and nab-paclitaxel plus gemcitabine have demonstrated superior outcomes over gemcitabine for advanced disease and have become standard chemotherapy regimens. No survival difference was observed for stage III disease (mOS: 16.7 vs. 14.8 months, P=0.76), while outcomes for stage IV improved (mOS: 4.76 vs. 9.99 months, P<0.001). This 23-year analysis highlights the evolving treatment landscape and improved outcomes in PA with the introduction of more effective therapies."

Journal • Retrospective data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

RiLEY: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - P2 | N=7 | Terminated | Sponsor: Anwaar Saeed | N=32 ➔ 7

Enrollment change • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

MountainTAP-29: A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (clinicaltrials.gov) - P2/3 | N=590 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P2/3 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

VELOCITY-Lung: Study of Novel Treatment Combinations in Patients With Lung Cancer (clinicaltrials.gov) - P2 | N=593 | Recruiting | Sponsor: Gilead Sciences | Trial completion date: Jan 2027 ➔ Dec 2028

Trial completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1

GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma. (PubMed, Cancer Biol Med) - "The GPRC5A-CXCL8-NET-cfDNA axis has a critical role in the development of therapeutic resistance to GnP in PDAC. Targeting this axis may represent a promising strategy for overcoming GnP resistance and thereby enhancing the efficacy of chemotherapy in PDAC."

Journal • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CXCL8 • GPRC5A • NLRP3

Amphiphilic albumin-based nanoparticles designed for the efficient delivery of taxanes. (PubMed, Int J Pharm) - "In cancer chemotherapy, taxanes such as Paclitaxel (PTX), Docetaxel (DTX), and Cabazitaxel (CTX) play a pivotal role but often require surfactants and solvents for solubilization, which cause adverse effects. In vivo biodistribution studies further confirmed enhanced tumor deposition when compared with Abraxane. These findings suggest that HSA-PLA nanoparticles may represent a significant advancement in clinical oncology by minimizing the reliance on surfactants and overcoming the limitations of current nab technology."

Journal • Oncology

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Hua Zhang | Trial primary completion date: Aug 2025 ➔ Sep 2026

Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

ADAPT-MRD: Adjuvant Pancreatic Therapy Guided by MRD (clinicaltrials.gov) - P=N/A | N=856 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting

Circulating tumor DNA • Enrollment open • Oncology • Pancreatic Cancer • Solid Tumor

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). (BASCO-MN 2025) - No abstract available

Late-breaking abstract • Metastases • P3 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Long-Term Survival in Pancreatic Adenocarcinoma with Metachronous Hepatic Metastases Using Multimodality Treatment Including Pegylated Liposomal Irinotecan and Capecitabine: A Case Report. (PubMed, Case Rep Oncol) - "Pegylated liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) has achieved a median overall survival of 6.1 months in patients with metastatic pancreatic ductal adenocarcinoma who progressed on gemcitabine-based chemotherapy...Adjuvant chemotherapy with FOLFIRINOX (5-FU, LV, irinotecan, and oxaliplatin) was given for 9 cycles between September 2018 and January 2019, and the patient remained recurrence-free until a computed tomography scan revealed soft tissue mesenteric infiltrations in July 2020. First-line palliative chemotherapy with nab-paclitaxel + gemcitabine was initiated and continued until January 2022 when disease progression in the form of two metastatic hepatic lesions was observed...This patient achieved an extraordinary survival of 25 months with second-line treatment with nal-IRI + CAP. Nal-IRI-based therapy has the potential to provide long-term survival in the presence of favourable prognostic factors such as..."

Journal • Hepatocellular Cancer • Hepatology • Oncology • Pain • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

TAB-2: Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients (clinicaltrials.gov) - P3 | N=220 | Recruiting | Sponsor: Tata Memorial Centre

New P3 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Management of Pancreatectomy for Pancreatic Cancer in a Patient With Annular Portal Pancreas: A Case Report. (PubMed, Cureus) - "We describe our experience of a case with PAP and review the literature on pancreatectomy in patients with PAP. A 72-year-old male presented to our department with a pancreatic body mass with a history of previous abdominal surgeries, who underwent distal pancreatectomy (DP) with lymphadenectomy following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel. His postoperative course was uneventful without POPF, and he was discharged on postoperative day 11. In conclusion, when PAP is suspected in patients with pancreatic cancer, understanding the accurate anatomy of the pancreas is essential to determine the surgical technique and a suitable choice of device for the transection of pancreatic parenchyma for reducing POPF."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov) - P1 | N=102 | Active, not recruiting | Sponsor: Genentech, Inc. | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Checkpoint inhibition • Trial completion date • Trial primary completion date • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Urothelial Cancer

Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial (ESMO-GI 2025) - P3 | "In a previous phase 1b study (ARC-8), quemliclustat combined with nab-paclitaxel (nP) plus gemcitabine (Gem) demonstrated a promising signal in median OS without a significant increase in toxicity.Trial design: PRISM-1 is a randomized, placebo-controlled, double-blind, global, multicenter, phase 3 trial evaluating the efficacy and safety of quemliclustat in treatment-naive patients with metastatic PDAC. The safety and tolerability of quemliclustat in combination with nP-Gem will be assessed; adverse events will be graded according to NCI CTCAE 5.0. Recruitment is planned across Asia, Australia, Europe, and North America."

Clinical • Metastases • P3 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CD73 • NT5E

Early safety and efficacy from the phase IIIb TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC) (ESMO-GI 2025) - P3 | "Early safety and efficacy data are reported. Participants (pts) received D 1500 mg with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin, carboplatin, cisplatin [cis], tegafur-gimeracil-oteracil [S-1], cis + S-1, or cis + nab-paclitaxel). The safety profiles of all study tx were manageable. ORR data are immature but overall ORR is comparable to the TOPAZ-1 study."

Clinical • Combination therapy • Metastases • P3 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer. (PubMed, Int J Cancer) - "We explored the feasibility and efficacy of sintilimab plus two-drug chemotherapy (S-1 plus nab-paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China...The safety profile was manageable. Sintilimab plus chemotherapy and apatinib followed by conversional resection may be a new feasible and safe option for initially unresectable gastric cancer, potentially leading to long-term survival or even cure."

Journal • Gastric Cancer • Oncology • Solid Tumor

Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. (PubMed, World J Gastrointest Surg) - "The combination of sintilimab with nab-paclitaxel + S-1 for neoadjuvant treatment of LAGC improved efficacy in patients without increasing adverse drug reactions and perioperative adverse events, suggesting that this treatment regimen is safe and feasible."

Journal • Gastric Cancer • Oncology • Solid Tumor

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (clinicaltrials.gov) - P3 | N=1000 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

Monotherapy • New P3 trial • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (clinicaltrials.gov) - P3 | N=812 | Recruiting | Sponsor: Henan Cancer Hospital

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor